Matches in SemOpenAlex for { <https://semopenalex.org/work/W2796090838> ?p ?o ?g. }
- W2796090838 abstract "Background Survival for stage I to III, hormone receptor‐positive, breast cancer has substantially improved over time due to advances in screening, surgery and adjuvant therapy. However many adjuvant therapies have significant treatment‐related toxicities, which worsen quality of life for breast cancer survivors. Postmenopausal women with hormone receptor‐positive breast cancer are now prescribed aromatase inhibitors (AI) as standard, with longer durations of therapy, up to 10 years, being considered for certain women. AI treatment is associated with a high incidence of AI‐induced musculoskeletal symptoms (AIMSS), often described as symmetrical pain and soreness in the joints, musculoskeletal pain and joint stiffness. AIMSS reduces compliance with AI therapy in up to one half of women undergoing adjuvant AI therapy, potentially compromising breast cancer outcomes. Exercise has been investigated for the prevention and treatment of AIMSS but the effect of this intervention remains unclear. Objectives To assess the effects of exercise therapies on the prevention or management of aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS) in women with stage I to III hormone receptor‐positive breast cancer. Search methods We searched Cochrane Breast Cancer's Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL databases up to 13 December 2018. We also searched two conference proceedings portals and two clinical trials registries for ongoing studies or unpublished trials, or both, in August 2019. We also reviewed reference lists of the included studies. Selection criteria We included randomised controlled trials that compared exercise versus a comparator arm. We did not impose any restriction on the comparator arm, which could include an alternative type of exercise, no exercise or a waiting list control. Both published and non‐peer‐reviewed studies were eligible. Data collection and analysis Two review authors independently extracted data, assessed risk of bias and certainty of the evidence using the GRADE approach. The outcomes investigated were pain, joint stiffness, grip strength, health‐related quality of life, cancer‐specific quality of life, adherence to AI therapy, adverse events, incidence of AIMSS, breast cancer‐specific survival and overall survival. For continuous outcomes that were assessed with the same instrument, we used the mean difference (MD); for those outcomes that used different instruments, we used the standardised mean difference (SMD) for the analysis. For dichotomous outcomes, we reported outcomes as an odds ratio (OR). Main results We included seven studies with 400 randomised participants; one study assessed exercise for preventing AIMSS and six studies assessed treating AIMSS. For preventing AIMSS, the single study reported no difference in pain scores, grip strength or compliance to taking AI medication between groups. Data values were not provided in the study and no other outcomes were reported. For managing AIMSS, we found that the evidence for the effect of exercise therapies on overall change in worst pain scores was very uncertain (SMD −0.23, 95% confidence interval (CI) −0.78 to 0.32; 4 studies, 284 women; very low‐certainty evidence). The evidence suggested that exercise therapies result in little to no difference in overall change in stiffness scores (Western Ontario McMasters Universities Osteoarthritis Index (WOMAC) stiffness score MD −0.76, 95% CI −1.67 to 0.15 and Visual Analogues Scale (VAS) stiffness score MD −0.42, 95% CI −2.10 to 1.26; 1 study, 53 women; low‐certainty evidence). The evidence was very uncertain for the outcomes of overall change in grip strength (MD 0.30, 95% CI −0.55 to 1.15; 1 study, 83 women; very low‐certainty evidence); overall change in health‐related quality of life (subscales of SF‐36 tool ranged from least benefit of MD 1.88, 95% CI −2.69 to 6.45 to most benefit of MD 9.70, 95% CI 1.67 to 17.73; 2 studies, 123 women, very low‐certainty evidence); overall change in cancer‐specific quality of life (MD 4.58, 95% CI −0.61 to 9.78; 2 studies, 136 women; very low‐certainty evidence); and adherence to aromatase inhibitors (OR 2.43, 95% CI 0.41 to 14.63; 2 studies, 224 women; very low‐certainty evidence). There were no adverse events identified across four studies in either arm (0 events reported; 4 studies; 331 participants; low‐certainty evidence). There were no data reported on incidence of AIMSS, breast cancer‐specific survival or overall survival. Authors' conclusions Given the wide‐ranging benefits of exercise for people affected by cancer, it was surprising that this review provided no clear evidence of benefit for exercise therapies in women with early breast cancer with AIMSS. This review only yielded seven eligible studies with 400 participants, which is likely to have underpowered the findings. The meta‐analysis was challenging due to the considerable heterogeneity amongst the trials, with a wide range of exercise regimens and follow‐up periods. Despite these inconclusive findings, exercise needs to be part of routine care for women with breast cancer due to its wide‐ranging benefits. Future research in this area would be enhanced with further understanding of the mechanism of AIMSS, a single clear definition of the condition, and phase III randomised controlled trials that are adequately powered to test targeted exercise interventions on the key clinical outcomes in this condition." @default.
- W2796090838 created "2018-04-13" @default.
- W2796090838 creator A5001932051 @default.
- W2796090838 creator A5008329588 @default.
- W2796090838 creator A5020828104 @default.
- W2796090838 creator A5027481104 @default.
- W2796090838 date "2020-01-29" @default.
- W2796090838 modified "2023-10-16" @default.
- W2796090838 title "Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer" @default.
- W2796090838 cites W1504993426 @default.
- W2796090838 cites W1518728900 @default.
- W2796090838 cites W1568019536 @default.
- W2796090838 cites W1602521239 @default.
- W2796090838 cites W1616537603 @default.
- W2796090838 cites W1758747032 @default.
- W2796090838 cites W1829077072 @default.
- W2796090838 cites W1981370136 @default.
- W2796090838 cites W1999460674 @default.
- W2796090838 cites W2011242432 @default.
- W2796090838 cites W2021181591 @default.
- W2796090838 cites W2023556159 @default.
- W2796090838 cites W2032506622 @default.
- W2796090838 cites W2043714777 @default.
- W2796090838 cites W2045462605 @default.
- W2796090838 cites W2047996370 @default.
- W2796090838 cites W2058408716 @default.
- W2796090838 cites W2058674588 @default.
- W2796090838 cites W2060507602 @default.
- W2796090838 cites W2068854823 @default.
- W2796090838 cites W2071003201 @default.
- W2796090838 cites W2077880074 @default.
- W2796090838 cites W2086018598 @default.
- W2796090838 cites W2094232837 @default.
- W2796090838 cites W2095152479 @default.
- W2796090838 cites W2099786312 @default.
- W2796090838 cites W2102535994 @default.
- W2796090838 cites W2105626129 @default.
- W2796090838 cites W2106117450 @default.
- W2796090838 cites W2107519665 @default.
- W2796090838 cites W2112180152 @default.
- W2796090838 cites W2113882443 @default.
- W2796090838 cites W2115776903 @default.
- W2796090838 cites W2125435699 @default.
- W2796090838 cites W2131208412 @default.
- W2796090838 cites W2138141504 @default.
- W2796090838 cites W2143543192 @default.
- W2796090838 cites W2144536165 @default.
- W2796090838 cites W2147312821 @default.
- W2796090838 cites W2148441650 @default.
- W2796090838 cites W2148560487 @default.
- W2796090838 cites W2150962478 @default.
- W2796090838 cites W2151799362 @default.
- W2796090838 cites W2152427545 @default.
- W2796090838 cites W2154734961 @default.
- W2796090838 cites W2158378066 @default.
- W2796090838 cites W2169092705 @default.
- W2796090838 cites W2169649287 @default.
- W2796090838 cites W2179951467 @default.
- W2796090838 cites W2214665719 @default.
- W2796090838 cites W2225480285 @default.
- W2796090838 cites W2227813149 @default.
- W2796090838 cites W2238407075 @default.
- W2796090838 cites W2297531972 @default.
- W2796090838 cites W2299726081 @default.
- W2796090838 cites W2304013124 @default.
- W2796090838 cites W2413469016 @default.
- W2796090838 cites W2415849069 @default.
- W2796090838 cites W2468345210 @default.
- W2796090838 cites W2514436481 @default.
- W2796090838 cites W2533707698 @default.
- W2796090838 cites W2547690040 @default.
- W2796090838 cites W2555275656 @default.
- W2796090838 cites W2565372774 @default.
- W2796090838 cites W2582402304 @default.
- W2796090838 cites W2587696304 @default.
- W2796090838 cites W2588517368 @default.
- W2796090838 cites W2589490797 @default.
- W2796090838 cites W2591243765 @default.
- W2796090838 cites W2606229968 @default.
- W2796090838 cites W2608382009 @default.
- W2796090838 cites W2611956337 @default.
- W2796090838 cites W2623921440 @default.
- W2796090838 cites W2654541509 @default.
- W2796090838 cites W2732206834 @default.
- W2796090838 cites W2734361740 @default.
- W2796090838 cites W2738765264 @default.
- W2796090838 cites W2744960472 @default.
- W2796090838 cites W2772364453 @default.
- W2796090838 cites W2792768998 @default.
- W2796090838 cites W2806866264 @default.
- W2796090838 cites W2810945438 @default.
- W2796090838 cites W2894702487 @default.
- W2796090838 cites W2904991649 @default.
- W2796090838 cites W2917150406 @default.
- W2796090838 cites W2922261874 @default.
- W2796090838 cites W2947309562 @default.
- W2796090838 cites W2981263606 @default.
- W2796090838 cites W2991792334 @default.
- W2796090838 cites W3037943088 @default.
- W2796090838 cites W4237015088 @default.